Clinical Trial Update: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating IMM01 plus azacitidine versus placebo plus azacitidine in newly diagnosed chronic myelomonocytic leukemia is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• IMM01 (IMM01)

Snippet

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Conditions: Chronic Myelomonocytic Leukemia | Phase 3 | Status: RECRUITING